For the quarter ended September 2025, Immunocore Holdings PLC Sponsored ADR (IMCR Quick QuoteIMCR - Free Report) reported revenue of $103.69 million, up 29.2% over the same period last year. EPS came in at $0, compared to $0.17 in the year-ago quarter.

The reported revenue represents a surprise of +3.8% over the Zacks Consensus Estimate of $99.9 million. With the consensus EPS estimate being -$0.30, the EPS surprise was +100%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Immunocore performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Revenue- United States: $67.3 million compared to the $66.05 million average estimate based on two analysts. The reported number represents a change of +17.5% year over year.
• Geographic Revenue- International: $2.87 million versus the two-analyst average estimate of $0.98 million. The reported number represents a year-over-year change of +52.3%.
• Geographic Revenue- Europe: $33.53 million compared to the $35.38 million average estimate based on two analysts. The reported number represents a change of +58.9% year over year.

View all Key Company Metrics for Immunocore here>>>

Shares of Immunocore have returned -9.4% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.